To study the efficacy of screening panel including interleukin-6 in diagnosis of neonatal sepsis

---

Original Article

Author Details : Archana Dubey, Sagar Narang*, Anita Pandey, Vandana Singh, Devyani Sharma

Volume : 5, Issue : 2, Year : 2019

Article Page : 62-65

https://doi.org/10.18231/j.ijmpo.2019.014

Suggest article by email

Get Permission

---

Abstract

Objective: To Study the Efficacy of Screening Panel, Including Interleukin 6, in Diagnosis of Neonatal Sepsis.
Materials and Methods: This prospective study was done from 2015-2016 in the Post Graduate department of Pediatrics of Subharti Medical College, Meerut. 100 neonates below the age of 28 days with a clinical suspicion of neonatal sepsis were enrolled in the study. Septic panel (WBC, ANC, I/T ratio, Micro ESR, CRP), IL-6 and blood culture were sent for screening. Data was collected and analyzed in babies having a positive blood culture. Septic panel in blood culture positive babies with >3variables of septic panel without IL-6, were compared with septic panel in blood culture positive babies with > 3 variables of septic panel with IL-6. Data was analyzed.
Result: Presence of the new marker (IL-6) with the septic panel shows a sensitivity of 65.71%, specificity of 96.92% and PPV of 92.0% against the septic panel without IL-6, which shows a sensitivity of 34.28%, specificity of 93.84% and PPV of 75.0%.
Conclusion: Septic panel with IL-6 has more sensitivity, specificity and positive predictive value as compared to septic panel without IL-6.

Keywords: Neonatal sepsis, Interleukin-6.

How to cite : Dubey A , Narang S , Pandey A, Singh V, Sharma D , To study the efficacy of screening panel including interleukin-6 in diagnosis of neonatal sepsis. IP Int J Med Paediatr Oncol 2019;5(2):62-65

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.